What was 10x Genomics, Inc.'s revenue in fiscal 2025?

10x Genomics, Inc. reported revenue of $0.64B for fiscal 2025, up 5.2% from fiscal 2024.

What is 10x Genomics, Inc.'s net margin?

Operating margin was -9.5% and net margin was -6.8%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.

Are 10x Genomics, Inc. insiders buying or selling shares?

Over the past 12 months, insiders reported 50 open-market sales totalling $16.9M on Form 4.

Which institutions hold 10x Genomics, Inc. stock?

527 institutions reported holding 10x Genomics, Inc. shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Abigail P. Johnson's.

Overview

10x Genomics, Inc.

TXGNASDAQHealth CareLaboratory Analytical InstrumentsCIK 0001770787

Latest 10-K: FY2025, filed Feb 13, 2026 · Open the 10-K (Inline XBRL) ↗

Ask about TXG in Workspace

Revenue: $0.64B; 5.2%YoYup from FY2024; TotalRevenue
Gross profit: $0.44B; 7.1%YoYup from FY2024; GrossProfit
Operating income: -$0.06B; n/mYoY; OperatingIncome
Net income: -$0.04B; n/mYoY; NetIncome
Diluted EPS: -$0.35; n/mYoY; EPSDiluted
Diluted shares: 124.7M; 3.6%YoYup from FY2024; WeightedAvgSharesDiluted

At a glance

Growth

10x Genomics, Inc. reported revenue of $0.64B for fiscal 2025, up 5.2% from fiscal 2024.
Revenue grew faster than the median S&P 500 member in 2 of the last 5 fiscal years.

Profitability

Operating margin was -9.5% and net margin was -6.8%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.

Per share

Diluted EPS was -$0.35.

Insiders & holders

Over the past 12 months, insiders reported 50 open-market sales totalling $16.9M on Form 4.
527 institutions reported holding 10x Genomics, Inc. shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Abigail P. Johnson's.

Written from the filed figures on this page by fixed rules — no AI.

Data as of Oct 23, 2026 · Sources: SEC EDGAR 10-K, Form 4, 13F

Quick answers

What was 10x Genomics, Inc.'s revenue in fiscal 2025?: 10x Genomics, Inc. reported revenue of $0.64B for fiscal 2025, up 5.2% from fiscal 2024.
What is 10x Genomics, Inc.'s net margin?: Operating margin was -9.5% and net margin was -6.8%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.
What is 10x Genomics, Inc.'s diluted EPS?: Diluted EPS was -$0.35.
Are 10x Genomics, Inc. insiders buying or selling shares?: Over the past 12 months, insiders reported 50 open-market sales totalling $16.9M on Form 4.
Which institutions hold 10x Genomics, Inc. stock?: 527 institutions reported holding 10x Genomics, Inc. shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Abigail P. Johnson's.

Data as of Oct 23, 2026 · Sources: SEC EDGAR 10-K

Financial statements

Annual figures from the 10-K, most recent fiscal year first.

Income Statement

5 annual periods

Chip: YoY change.

Income Statement, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: S&P 500 median change. Line under a label: how many S&P 500 companies its median rests on.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	4Y CAGR
Revenue	$642.82M5.2%up S&P 500 6.4%	$610.78M1.3%down S&P 500 4.5%	$618.73M19.8%up S&P 500 4.8%	$516.41M5.3%up S&P 500 10.3%	$490.49M64.1%up S&P 500 13.8%	7.0% S&P 500 6.6%
Gross Profit Median of 315 / 498	$443.88M7.1%up S&P 500 6.8%	$414.48M1.3%up S&P 500 5.5%	$409.31M3.4%up S&P 500 5.2%	$396.02M4.9%down S&P 500 8.3%	$416.40M73.2%up S&P 500 15.7%	1.6% S&P 500 6.2%
Operating Income Median of 373 / 498	negative: -$60.98Mn/m S&P 500 7.3%	negative: -$194.56Mn/m S&P 500 7.4%	negative: -$265.33Mn/m S&P 500 4.9%	negative: -$167.94Mn/m S&P 500 7.5%	negative: -$52.25Mn/m S&P 500 23.5%	n/m S&P 500 7.2%
Net Income	negative: -$43.54Mn/m S&P 500 4.8%	negative: -$182.63Mn/m S&P 500 5.7%	negative: -$255.10Mn/m S&P 500 1.9%	negative: -$166.00Mn/m S&P 500 1.3%	negative: -$58.22Mn/m S&P 500 33.9%	n/m S&P 500 4.1%
EPS (Diluted)	negative: -$0.35n/m S&P 500 6.2%	negative: -$1.52n/m S&P 500 7.9%	negative: -$2.18n/m S&P 500 1.9%	negative: -$1.46n/m S&P 500 1.5%	negative: -$0.53n/m S&P 500 34.8%	n/m S&P 500 5.6%

Balance Sheet

5 annual periods

Chip: YoY change.

Balance Sheet, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: S&P 500 median change. Line under a label: how many S&P 500 companies its median rests on.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	4Y CAGR
Total Assets	$1.04B13.4%up S&P 500 5.6%	$0.92B4.8%down S&P 500 3.4%	$0.97B6.2%down S&P 500 4.1%	$1.03B1.0%up S&P 500 2.2%	$1.02B9.6%up S&P 500 6.7%	0.5% S&P 500 4.7%
Total Liabilities Median of 357 / 498	$245.04M17.5%up S&P 500 6.4%	$208.50M7.0%down S&P 500 1.9%	$224.10M0.4%up S&P 500 2.9%	$223.24M10.9%up S&P 500 2.0%	$201.26M5.8%up S&P 500 5.2%	5.0% S&P 500 4.4%
Stockholders' Equity	$796.33M12.1%up S&P 500 6.8%	$710.13M4.2%down S&P 500 5.4%	$741.04M8.0%down S&P 500 7.3%	$805.74M1.4%down S&P 500 2.5%	$817.57M10.6%up S&P 500 9.0%	-0.7% S&P 500 6.1%
Cash & Equivalents	—	$344.07M4.2%down S&P 500 1.9%	$359.28M63.5%up S&P 500 6.7%	$219.75M62.6%down S&P 500 -8.6%	$587.45M11.5%down S&P 500 -2.9%	— S&P 500 2.0%
Total Debt Median of 393 / 498	—	—	—	—	—	— S&P 500 3.7%

Cash Flow Statement

5 annual periods

Chip: YoY change.

Cash Flow Statement, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: S&P 500 median change. Line under a label: how many S&P 500 companies its median rests on.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	4Y CAGR
Operating Cash Flow	$136.05M1941.6%up S&P 500 6.3%	$6.66Mn/m S&P 500 4.8%	negative: -$15.20Mn/m S&P 500 9.9%	negative: -$33.61Mn/m S&P 500 -0.7%	negative: -$21.37Mn/m S&P 500 10.7%	n/m S&P 500 7.0%
Capital Expenditures	$5.93M52.1%down S&P 500 5.4%	$12.39M74.5%down S&P 500 2.8%	$48.60M63.1%down S&P 500 11.3%	$131.66M30.0%up S&P 500 14.0%	$101.28M176.2%up S&P 500 8.1%	-50.8% S&P 500 9.0%
Free Cash Flow Median of 378 / 498	$130.12Mn/m S&P 500 7.3%	negative: -$5.73Mn/m S&P 500 6.1%	negative: -$63.80Mn/m S&P 500 8.8%	negative: -$165.27Mn/m S&P 500 -11.3%	negative: -$122.65Mn/m S&P 500 10.2%	n/m S&P 500 4.9%

n/m: not meaningful — the base (the prior year, or the first year for the CAGR) was zero or negative, or a per-share figure’s share basis changed (stock split). “—” means the figure is not available.

S&P 500 median = median of the companies in the index on Dec 31 of each fiscal year, from their own 10-K filings; a change counts only companies whose prior year was positive. Each median uses every member that reports the line item; where fewer than 80% do (banks and insurers file no gross profit), the row names how many. Published where at least 250 companies report it. Updated 2026-10-20. This compares reported figures, not share-price returns. Methodology

Ratios & valuation

FY2025

Every ratio read two ways: Wall Street’s popular formula and the value investor’s stricter one. Same question, same unit. Pick a ratio.

Valuation · Earnings yield

What a dollar of market value earned

n/m

Wall Street

on net earnings

FY2024 n/m

6.4%

Value investor

on free cash flow

FY2024 negative: −0.3%

How it’s calculated

Wall Street · on net earnings

Diluted EPS ÷ fiscal-year-end share price (1 ÷ P/E)

pe_ratio (ratio table)

P/E n/m

Value investor · on free cash flow

(Operating cash flow − capital expenditures) ÷ market capitalisation (fiscal-year-end close × weighted-average diluted shares)

free cash flow ÷ market cap

Each ratio measures one thing two ways, in the same unit: the popular formula, then a stricter one, so a lower figure is the stricter reading. Gap = value-investor figure minus Wall Street figure, from the figures shown.

Price-based ratios use the fiscal-year-end closing price. Free cash flow = operating cash flow − capital expenditures (we compute it; filings rarely report it). n/m = not meaningful (denominator ≤ 0); “—” = not reported. Each ratio’s formulas are under “How it’s calculated”.

Cash & capital allocation

Where the cash went in FY2025, from the 10-K cash flow statement.

Operating cash flow: $136.05M
Capex: $5.93M
Free cash flow: $130.12M
R&D: $238.63M
Buybacks: —
Dividends: —
Debt repaid: —
Debt issued: —
Net debt change: —

Uses of operating cash flow, FY2025

Capex4.4%

Each use is shown against operating cash flow on its own; the uses overlap.

Free cash flow by year

FY21-$122.65M
FY22-$165.27M
FY23-$63.80M
FY24-$5.73M
FY25$130.12M

Buybacks by year

FY21—
FY22—
FY23—
FY24—
FY25—

Smart money

Who is trading and holding 10x Genomics, Inc., from Form 4, 13F and 13D/13G filings.

Insiders

Insider activity · past 12 months

Open-market trades reported on Form 4 in the past 365 days.

Buys: 0; none reported
Sales: 50; 6 insiders
Value sold: $16.9M
Shares sold: 381,782
Net shares: -381,782; bought minus sold
Last trade: Sep 22, 2026

Purchases 0% of valueSales 100% of value

Latest open-market insider trades from Form 4
Insider	Type	Date	Shares	Price	Value	Filing
SULIMAN SHEHNAAZDirector	Sell	Sep 22, 2026	292	$78.20	$22,833	View filing on SEC EDGAR
SULIMAN SHEHNAAZDirector	Sell	Sep 22, 2026	614	$79.51	$48,820	View filing on SEC EDGAR
SULIMAN SHEHNAAZDirector	Sell	Sep 22, 2026	1,325	$80.82	$107,082	View filing on SEC EDGAR

See plans

Open-market purchases (code P) and sales (code S) only. Grants, option exercises and tax withholding are excluded. Sales may be made under pre-arranged Rule 10b5-1 plans.

Ownership

Largest institutional holders

13F

Quarter ended Jun 30, 2026; change versus Mar 31, 2026.

Institutions reporting: 527
Top 3 hold: 25.7%; of 124.75M diluted shares, FY2025 10-K

Top 3 holders, share of diluted sharesof 100%

Abigail P. Johnson12.1%
15,103,608 sh · $579.1MAdded 668.7%13F-HR · Jun 30, 2026 on SEC EDGAR
Catherine D. Wood8.0%
10,003,057 sh · $383.5MTrimmed 14.6%13F-HR · Jun 30, 2026 on SEC EDGAR
Vanguard Portfolio Management5.6%
6,982,492 sh · $267.7MAdded 1.0%13F-HR · Jun 30, 2026 on SEC EDGAR

See plans

Some filers' amendments could not be read, so a few holders may be counted twice.

Bars: share of diluted shares on a shared scale; the tick marks 5%. 13F filings are due 45 days after quarter end, so this is the latest fully reported quarter. Amended filings are counted once.

Blockholders, 5% and over

13D/G

SC 13D / 13G, latest filing per filer.

Filers at 5%+: 9
Combined: 74.0%; sum of latest filings
Activist (13D): 0

5%+ filers, share of the class as filedof 100%

FMR LLC15.6%
Passive · 13GSC 13G/A · Mar 6, 2026 on SEC EDGAR
T. Rowe Price Associates, Inc.11.7%
Passive · 13GSC 13G · Sep 8, 2026 on SEC EDGAR
ARK Investment Management LLC10.75%
Passive · 13GLast filed 2 yrs agoSC 13G · Aug 12, 2024 on SEC EDGAR

See plans

No filer switched from a passive 13G to an activist 13D in the last 365 days.

Percent of the class as each filer last reported it; filings older than a year may no longer reflect the stake. Latest filing per filer within three years; a later filing reporting 0% removes the filer.

Full history, every insider and 13F filer, 13D/G activist stakes, and webhooks are on Institutional.

See Institutional

Smart money

Showing the most recent 5 annual periods. Get longer history on the Pro plan, or the full history (1993–present) plus the smart-money dataset and webhooks on Institutional.

Restatement Radar

6 numbers 10x Genomics, Inc. later changed — same XBRL tag, both filings linked.

numbers changed: 6
restating filings: 4
came with an amendment or a non-reliance notice: 0

Feb 26, 2021 · 10-K
changed 2 numbers
No amendment filed
Open filing
- Accrued expensesAs of Dec 31, 2019$3.8M restated to $182K−95.2%
  As reported · Feb 27, 2020us-gaap:OtherEmployeeRelatedLiabilitiesCurrent
- Other noncurrent liabilitiesAs of Dec 31, 2019$1.1M restated to $1.9M+76.4%
  As reported · Feb 27, 2020us-gaap:OtherLiabilitiesNoncurrent
Feb 18, 2022 · 10-K
changed 1 number
No amendment filed
Open filing
- Other noncurrent assetsAs of Dec 31, 2020$26.7M restated to $4.3M−83.8%
  As reported · Feb 26, 2021us-gaap:OtherAssetsNoncurrent
Feb 16, 2023 · 10-K
changed 2 numbers
No amendment filed
Open filing
- Accrued expensesAs of Dec 31, 2021$378K restated to $3.2M+757.9%
  As reported · Feb 18, 2022us-gaap:OtherEmployeeRelatedLiabilitiesCurrent
- Other current liabilitiesAs of Dec 31, 2021$5.3M restated to $8.3M+57.1%
  As reported · Feb 18, 2022us-gaap:OtherLiabilitiesCurrent
Feb 12, 2026 · 10-K
changed 1 number
No amendment filed
Open filing
- Impairment chargesFY 2023$4.6M restated to $9.8M+113.0%
  As reported · Feb 15, 2024us-gaap:ImpairmentOfLongLivedAssetsHeldForUse

TXG is not the only one.

See every restatement we've found across the market — or get an alert the next time TXG revises a number.

Restatement Radar Alert me

Restatements are detected by comparing every vintage of a fact across all of 10x Genomics, Inc.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows TXG's most significant revisions, and a figure absent from it has not been certified as unrevised.

Peers, filings & research

Sector Peers

UNITEDHEALTH GROUP INC

MRK· Health Care

Merck & Co., Inc.

TMO· Health Care

THERMO FISHER SCIENTIFIC INC.

ABT· Health Care

ABBOTT LABORATORIES

ISRG· Health Care

INTUITIVE SURGICAL INC

AMGN· Health Care

AMGEN INC

Recent SEC filings

The six newest, periodic reports and 8-Ks together. Dates are SEC filing dates.

All filings on EDGAR

Six most recent SEC filings, newest first
Form	Filing	Filed	Document
10-Q	Quarterly report · Quarter ended Jun 30, 2026 0001628280-26-054491 · accepted Aug 6, 21:31 UTC	Aug 7, 2026	Open	Filed Aug 7, 2026 · 0001628280-26-054491
8-K	Current report (material events) · Event dated Aug 6, 2026 0001628280-26-054273 · accepted 20:03 UTC	Aug 6, 2026	Open	Filed Aug 6, 2026 · 0001628280-26-054273
8-K	Current report (material events) · Event dated Jun 4, 2026 0001628280-26-041651 · accepted 20:46 UTC	Jun 8, 2026	Open	Filed Jun 8, 2026 · 0001628280-26-041651
10-Q	Quarterly report · Quarter ended Mar 31, 2026 0001628280-26-032388 · accepted May 7, 21:36 UTC	May 8, 2026	Open	Filed May 8, 2026 · 0001628280-26-032388
10-K	Annual report · Fiscal year ended Dec 31, 2025 0001628280-26-007822 · accepted Feb 12, 22:38 UTC	Feb 13, 2026	Open	Filed Feb 13, 2026 · 0001628280-26-007822
10-K/A	Annual report amendment · Fiscal year ended Dec 31, 2020 0001770787-21-000023 · accepted 20:07 UTC	Apr 23, 2021	Open	Filed Apr 23, 2021 · 0001770787-21-000023

“Open” goes to the Inline XBRL viewer when the filing has one, else the primary document. The accession opens the EDGAR index.

Research Reports

No published research on TXG yet.

Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on TXG and publish the result to your public profile.

Browse the research catalog Generate one with your agent

The data behind this page

27 tables, history 1993–present. Every figure above is a row you can query.

Fundamentals

Standardized financial facts, ratios and filings.

fact: 120.5Mrows
ratio: 5.3Mrows
filing: 2.35Mrows
entity: 19,888rows

292 standard concepts.

Built from these SEC forms

10-K
10-K/A
10-K405
10-KT
10-Q
10-Q/A
10-QT
20-F
20-F/A
40-F
40-F/A
8-K
8-K/A
6-K
6-K/A
S-1
S-3
S-4
S-11
F-1
F-3
F-4
POS AM
10-KSBsoon
10-QSBsoon
DEF 14Asoon
DEF 14Csoon
DEFA14Asoon
PRE 14Asoon
DEFM14Asoon
425soon
SC TO-Tsoon
SC TO-Isoon
SC 14D9soon
SC 13E3soon
CORRESPsoon
NT 10-Ksoon
NT 10-Qsoon
NT 20-Fsoon
N-PORT-Psoon

Smart money

Insider and institutional filings.

institutional_holding: 59.5Mrows
insider_transaction: 11.4Mrows
insider_filing: 5.2Mrows
insider_ownership: 1.33Mrows

78M+ smart-money rows in all.

Built from these SEC forms

Form 3
Form 3/A
Form 4
Form 4/A
Form 5
Form 5/A
13F-HR
13F-HR/A
13F-NT
13F-NT/A
SC 13D
SC 13D/A
SC 13G
SC 13G/A
Form 144
Form 144/A

One real fact row for 10x Genomics, Inc.

Fact receiptOperatingCashFlow

Operating cash flow · FY2025

$0.14B

136,050,000 USD

10x Genomics, Inc. reported Operating cash flow of $136.1M for fiscal year 2025 in its 10-K filed Feb 13, 2026.

Fiscal period: 2025 FY
Period end: 2025-12-31
Form: 10-K
Filed: Feb 13, 2026
Entity (CIK): 0001770787

Provenance trail

Filed with the SEC
Form 10-K, filed Feb 13, 2026.
Accession 0001628280-26-007822
Open in the Inline XBRL viewer for 0001628280-26-007822
Reported in the filing
Operating cash flow for fiscal year 2025, the period ended 2025-12-31, in USD. Valuein maps the filed line to the standard concept OperatingCashFlow.
Stored as one fact row
Every channel returns this row with the same id.
fact_id 227d4bac74f7f5c52b550a912daec4172e06f5fbe7214913b13388355241c94c
Shown on this page
The same $0.14B appears in the Cash Flow Statement and in Cash & capital allocation.

fact rowjson

{  "entity_id": "0001770787",  "standard_concept": "OperatingCashFlow",  "fiscal_year": 2025,  "fiscal_period": "FY",  "period_end": "2025-12-31",  "numeric_value": 136050000,  "unit": "USD",  "accession": "0001628280-26-007822",  "fact_id": "227d4bac74f7f5c52b550a912daec4172e06f5fbe7214913b13388355241c94c"}

Get the same data

Get your free API key

bash

# Fact-level Parquet over HTTPS, every row traced to its filingcurl -H "Authorization: Bearer $VALUEIN_API_KEY" \  https://data.valuein.biz/v1/pro/fact/0001770787.parquet \  -o txg.parquet

Read the API docs

Terminalbash

# The same tables in your notebooks and backtests; the free sample needs no token$ pip install valuein-sdk

Python

from valuein_sdk import ValueinClient with ValueinClient() as client:    sql = """        SELECT fiscal_year, numeric_value FROM fact        WHERE entity_id = '0001770787'          AND standard_concept = 'TotalRevenue'          AND fiscal_period = 'FY'    """    print(client.run_query(sql))

Install the SDK

bash

# Connect Claude or ChatGPT to the same facts, each with a fact_idhttps://mcp.valuein.biz/mcp Ask your agent:get_company_fundamentals TXG   # CIK 0001770787

Connect the MCP server

bash

# Ask in plain English; every figure comes back cited to its filingTell me about TXG: a quick, cited overview I can dig into.

Open TXG in Workspace

One token unlocks every channel. SDK docs · MCP docs

Cite this page

Data as of Oct 23, 2026. Canonical address: https://valuein.biz/data/TXG

APA-style text

Valuein. (2026, October 23). 10x Genomics, Inc. (TXG) financial statements, earnings power and smart-money summary [Data set]. Source: SEC EDGAR filings. https://valuein.biz/data/TXG

BibTeX

@misc{valuein_txg_2026,
  author = {{Valuein}},
  title = {10x Genomics, Inc. (TXG) financial statements, earnings power and smart-money summary},
  year = {2026},
  howpublished = {\url{https://valuein.biz/data/TXG}},
  note = {Data as of 2026-10-23; source: SEC EDGAR filings}
}

Open 10-K in SEC Inline XBRL viewer

10-K filed Feb 13, 2026 · accession 0001628280-26-007822

Agents: every figure Valuein's tools return carries a fact_id that traces to its SEC filing.

point-in-time · survivorship-free · every number traceable to its SEC filing

View TXG filings on SEC EDGAR

At a glance

Growth

Profitability

Per share

Insiders & holders

02Financial statements

Income Statement

Balance Sheet

Cash Flow Statement

Ratios & valuation

03Cash & capital allocation

Uses of operating cash flow, FY2025

Free cash flow by year

Buybacks by year

04Smart money

Insiders

Insider activity · past 12 months

Ownership

Largest institutional holders

Blockholders, 5% and over

Smart money

Feb 26, 2021 · 10-K

Feb 18, 2022 · 10-K

Feb 16, 2023 · 10-K

Feb 12, 2026 · 10-K

06Peers, filings & research

Sector Peers

Recent SEC filings

Research Reports

07The data behind this page

Fundamentals

Built from these SEC forms

Smart money

Built from these SEC forms

One real fact row for 10x Genomics, Inc.

Provenance trail

Get the same data

08Cite this page

Insiders & holders

03Cash & capital allocation

Uses of operating cash flow, FY2025

Free cash flow by year

Buybacks by year

04Smart money

Insiders

Insider activity · past 12 months

Ownership

Largest institutional holders

Blockholders, 5% and over

Feb 26, 2021 · 10-K

Feb 18, 2022 · 10-K

Feb 16, 2023 · 10-K

Feb 12, 2026 · 10-K

Sector Peers

Recent SEC filings

07The data behind this page

Fundamentals

Built from these SEC forms

Smart money

Built from these SEC forms

One real fact row for 10x Genomics, Inc.

Provenance trail

Get the same data

Financial statements

Cash & capital allocation

Smart money

Peers, filings & research

The data behind this page

Cite this page

Cash & capital allocation

Smart money

The data behind this page